Replies to post #211809 on Biotech Values

[DewDiligence]

CHRS—Although no new clinical trials are required, the CRL will delay eventual approval by 12-18 months, IMO.

p.s. Two capable companies—CHRS and NVS—have now floundered in obtaining FDA approval for Neuasta FoBs.